UNIVERSITY OF LEICESTER & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE

STANDARD OPERATING PROCEDURES

University of Leicester (UoL) Research Governance Office
SOP S-1043 UoL

Version 1.1, September 2021

Processing and Reporting Serious Adverse Events, Serious Adverse Device Effects and Unexpected Serious Adverse Device Effects for Non CE Marked Medical Device Studies (Requiring MHRA Approval)
Sponsored by the University of Leicester

OFFICE BASE
Research Governance Office
Academic Department, Ground Floor
Leicester General Hospital
Gwendolen Road
Leicester
LE5 4PW

Effective Date: October 2021
1 Introduction

This Standard Operating Procedure (SOP) describes the process required by the University of Leicester (UoL) for identifying, documenting and reporting all adverse events (AEs) for non CE marked medical device studies (requiring approval by the MHRA) sponsored by University of Leicester.

In order to comply with the appropriate legislation, all researchers must be aware of the definitions and procedures in relation to AEs for medical device studies. This legislation includes:
- Medical Device Regulations 2002
- European Commission Guidelines on Medical Devices MEDDEV 2.7/3

2 Scope

This SOP applies to all staff and external individuals involved in research activity involving non-CE marked devices or CE marked devices that are being used outside their intended use(s) covered by the CE marking that require MHRA approval.

3 Definitions

3.1 Medical Device

A medical device is defined as any instrument, apparatus, appliance, material or other article, whether used alone or in combination with any software necessary for its proper application which is:

a) Intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific purpose(s) of:

- Diagnosis, prevention, monitoring, treatment or alleviation of disease
- Diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury
- Investigation, replacement, modification, or support of the anatomy or of a physiological process
- Supporting or sustaining life
- Control of contraception
- Disinfection of medical devices

b) Which does not achieve its primary intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its intended function by such means.
This definition of medical device is asper ISO 14155 Clinical investigation of medical devices for human subjects - Good Clinical Practice and does not apply to in vitro diagnostic medical devices (which is covered by ISO 13485:2003).

3.2 Investigational Medical Device
An Investigational Medical Device is a medical device being assessed for safety or performance in a clinical investigation. This includes medical devices already on the market that are being evaluated for new intended uses, new populations, new materials or design changes.

3.3 Device Deficiency
Inadequacy of a medical device related to its identity, quality, durability, reliability, safety or performance, such as malfunction, misuse or use error and inadequate labelling.

3.4 Device Malfunction
Failure of an investigational medical device to perform in accordance with its intended purpose when used in accordance with the instructions for use or Clinical Investigation Plan (CIP).

3.5 Clinical Investigation Plan (CIP)
A document that states the rationale, objectives, design and proposed analysis, methodology, monitoring, conduct and record keeping of the clinical investigation.

3.6 Investigator’s Brochure (IB)
A compilation of the current clinical and non-clinical information on the investigational medicinal device relevant to the clinical investigation.

3.7 Adverse Event (AE)
An adverse event (AE) is an untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device/intervention.

An AE can therefore be any unfavourable and unintended sign (including abnormal laboratory results), symptom or disease temporarily associated with the use of the investigational medical device/intervention, whether or not considered to be related to the investigational medical device/intervention.

3.8 Adverse Device Effect (ADE)
An adverse device effect (ADE) is an adverse event that is deemed to be related to the use of an investigational medical device. This includes any adverse event resulting from insufficiencies or inadequacies in the instructions for use, the deployment, the implantation, the installation, the operation, or any malfunction of the investigational medical device.
An ADE includes any event that is a result of use error or intentional misuse. Use error refers to an act or omission of an act that results in a different device response than intended by the manufacturer or expected by the user. An unexpected physiological response of the subject does not in itself constitute a use error.

3.9 Serious Adverse Event (SAE)
In medical device studies a Serious Adverse Event (SAE) is defined by ISO14155:2011 guidelines for medical device studies as an untoward occurrence in a trial subject that:

- led to a death
- led to serious deterioration in the health of the participant, that either resulted in:
  - a life-threatening illness or injury, or
  - a permanent impairment of a body structure or a body function
  - in patient hospitalisation or prolonged in-patient hospitalisation
  - medical or surgical intervention to prevent life threatening illness or injury or permanent impairment to a body structure or a body function.
  - led to foetal distress, foetal death or a congenital abnormality or birth defect.

NOTE 1: This also includes device deficiencies that might have led to a SAE if:
- suitable action have not been taken
- intervention had not been made
- if circumstances had been less fortunate

NOTE 2: A planned hospitalisation for a pre-existing condition, or procedure required by the Clinical Investigation Plan (CIP) without a serious deterioration in health is not considered to be a serious adverse event.

3.10 Serious Adverse Device Effect (SADE)
A SADE is an adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.

3.11 Anticipated Serious Adverse Device effect (ASADE)
A serious adverse device effect which by its nature, incidence, severity or outcome has been previously identified in the current version of the Risk Assessment or the Investigator's Brochure.

3.12 Unanticipated Serious Adverse Device Effect (USADE)
A serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the Risk Assessment and/or Investigator's Brochure.

4 Identification and Recording of Adverse Events
The Principal Investigator (PI) at site or designee, is responsible for the identification of any AE as defined in the protocol/CIP. AE/ADEs defined as non-serious in nature must be recorded in the medical records and the Adverse Event/Device Effect record (Appendix 2) and retained with the case report form (CRF), unless it forms part of the CRF and is agreed by the Sponsor.

All AE and ADEs must be observed to ensure that they do not escalate to an SAE/SADE. There are no requirements to report these events to the Sponsor or Regulatory Agencies unless the AE meets the criteria of a SAE where the procedure described in section 5 must be followed.
5 Reporting of Adverse Events

5.1 Reporting to Sponsor
All SAEs/SADEs/USADEs in studies sponsored by UoL must be reported to the Sponsor within 24 hours of the research team becoming aware of the event unless they are listed in the protocol/clinical investigation plan as expected events. UoL Serious Adverse Event/Device Effect Report Form C for medical device studies (Appendix 3) must be used. This form and associated completion guidance document are both available on the RGO Website. This form and any documents provided to the Sponsor in support of the SAE/SADE/USADE MUST be anonymised and MUST not contain any patient identifiable data.

For UoL Sponsored studies, the Chief Investigator (CI) or Principal Investigator (PI) or the Sponsor delegated qualified individual is responsible for the review and sign-off of all serious adverse event/effects. In the event that the CI/PI is unable to sign the report immediately, the research team/site should not delay sending the report, however a CI/PI signed copy must be forwarded to the Sponsor as soon as possible (and within 7 days of the initial reporting). The research team/site must provide any additional information actively following-up the subject until either:

- The SAE/SADE/USADE resolves, or
- Until 30 days after the discontinuation of use of the medical device

After discussion with, and in agreement by the Sponsor, it may be possible for additional medically qualified individuals to be delegated the responsibility for reviewing and signing off the SAE form.

5.1.1 Multi-Centre studies
All SAEs and SADEs from all sites must be sent to the Sponsor unless alternative arrangements have been agreed with the Sponsor. Where sites are managed through a third party contractor e.g. a Clinical Trials Unit it may be appropriate to make alternative arrangements for reporting. These arrangements will be specifically detailed in the third party agreement. All SAE/SADE will be reviewed by the Director of R&I at the monthly R&I Management Meeting, discussed at the Research Sponsorship Monitoring & Oversight Group (RSMOG), then ratified at the Research Sponsorship Committee (RSC). Should a USADE be reported at any site, the Sponsor will delegate the responsibility of informing all Principal Investigators involved in the study. Where required all medical devices at all sites will be quarantined until the MHRA investigation has been completed (see section 7).

5.2 Reporting to MHRA
The following events are considered reportable to the MHRA in accordance with Annex 7, section 2.3.5 and Annex X, section 2.3.5 of Directives 90/385/EC and 93/42/8EEC respectively:

- Any SAE
- Any device deficiency that might have led to a SAE if:
  - Suitable action had not been taken or
  - Intervention had not been made or
  - If circumstance had been less fortunate
- New findings/updates in relation to already reported events

For all reportable events where there is an imminent risk or death, serious injury or serious illness and that requires prompt remedial action for other patients/subjects, users or other
persons or a new finding to it: the sponsor or designee must report to the MHRA immediately, but no later than **2 calendar days** after they become aware of such an event or new information in relation to an already reported event.

Any other reportable events as outlined above or any new finding/update in relation to them must also be reported immediately, but no later than **7 calendar days** after the sponsor becomes aware of them.

The sponsor or designee must notify the MHRA using the template tabulation form detailed in the appendix of the MEDDEV 2.7/3 document (see Appendix 5). The table gives a cumulative overview of the reportable events per clinical investigation and must be updated and transmitted to the MHRA every time a new reportable event or new finding to an already reported event is received.

The sponsor or designee shall identify the new/updated information in the status column of the tabular form as outlined below:

- **a** = Added (new reportable event)
- **m** = Modified (new finding/update to an already reported event)
- **u** = unchanged

Changes in lines should be highlighted in bold and/or colour in the respective column.

The report should be sent as an Excel file to [aic@mhra.gsi.gov.uk](mailto:aic@mhra.gsi.gov.uk) quoting MHRA’s CI reference number or upload through MORE [https://aic.mhra.gov.uk](https://aic.mhra.gov.uk/) including the MHRA’s CI reference number in the “incident description” field. All correspondence must be copied to the Sponsor.

The letter of no objection from the MHRA will also detail whether summary reports (including their frequency) need to be submitted to the MHRA. The information to be submitted must be provided in tabular format as shown on the second tab of Appendix 5.

The letter of no objection will also detail whether protocol deviations must also be reported to the MHRA (see SOP S-1013).

**5.3 Reporting to REC**

The following SAEs/SADEs are considered reportable to the REC that gave the favourable ethical opinion:

- Those related to the administration of the medical device or any of the research procedures.
- USADEs- i.e. unanticipated events not listed in the Risk Assessment/Protocol as an anticipated occurrence.

Reports should be submitted within 15 days of the Chief Investigator becoming aware of the event using the Non-CTIMP Safety Report Form to the REC published on the HRA website [http://www.hra.nhs.uk/](http://www.hra.nhs.uk/)

The Chief Investigator is also required to include a report of the safety of participants in the annual progress report to the REC.

Individual reports will be reviewed by the REC at a subcommittee or committee meeting. Any requests for further information should be provided as applicable and all correspondence should be copied to the Sponsor.
5.4 Reporting to NHS Trust
Where applicable, SAEs, SADE or USADEs which occur at site must be reported on the Trusts electronic incident reporting system (e.g. Datix). Reporting of incidents must be carried out in accordance with the Trusts Incident and Accident reporting policy.

6 Assessment of Adverse Events
All assessments of AEs must be made by the Chief Investigator (CI)/Principal Investigator (PI) or the Sponsor agreed delegated medically qualified individual. The study Delegation of Authority and Signature Log must reflect this (Appendix 1 SOP S-1021 Informed consent for research sponsored by UoL).

Each AE must be assessed for seriousness, severity, causality and expectedness. Where there are two assessments of causality, for example, the CI/PI assessment do not concur, the causality made by the Investigator cannot be downgraded.

6.1 Assessment of Seriousness
The assessor should make an assessment of seriousness as defined in section 3 Serious Adverse Events.

6.2 Assessment of Severity
The relationship between the investigational medical device and the occurrence of each adverse event must be assessed utilising the device event categorisation flow chart (Appendix 1).

6.3 Assessment of Causality
The assessor of any causality assessments will use clinical judgement to determine the relationship. The assessor must consult the current version of the Risk Assessment and/or the Investigator’s Brochure where available.

When making a causality assessment, the following definitions should be used:

**Not related**
There is no evidence of causal relationship to the Investigational Device.

**Unlikely**
The relationship with the use of the investigational medical device seems not relevant and/or the event can be reasonably explained by another cause.

**Possible**
The relationship with the use of the investigational medical device is weak but cannot be ruled out completely.

**Probable**
The relationship with the investigational medical device seems relevant and/or the event cannot reasonably be explained by another cause.

**Causal Relationship**
The serious event is associated with the investigational medical device beyond reasonable doubt.

6.4 Assessment of Expectedness
The assessor must consult the current version of the Investigator brochure and/or Risk Assessment to determine where an event is expected. Where applicable in blinded studies, unblinding must occur to assess treatment assignment.

If the event is classified as an anticipated effect, which by its nature, incidence severity or outcome has been previously identified in the Risk Assessment and/or Investigator Brochure (IB) and/or the Protocol. This event does not require reporting to the Sponsor or Regulatory Agencies but must be recorded in the medical records and the adverse event record (Appendix 2). This document must be retained with the case report form unless it forms part of the case report form (CRF) and is agreed by the Sponsor. Where an event could be related to the medical device and is unanticipated in relation to the Investigator Brochure (IB)/Risk Assessment, the Investigator must report this event immediately or within 24hrs to the Sponsor/manufacturer and to the regulatory agencies within the required timelines.

7 Quarantine of Devices
The device must not be returned to the manufacturer until the MHRA has been given the opportunity to carry out/complete an investigation. In addition, the device should not be:

- Discarded
- Repaired
- Returned to the manufacturer
- Removed from the site / organisation premises without previous agreement from the Sponsor

All material evidence i.e. devices/parts removed, replaced or withdrawn from use following an incident, instructions for use, records of use, repair and maintenance records, packaging materials, or other means of batch identification must be:

- clearly identified and labelled
- stored securely

Evidence should not be interfered with in any way except for safety reasons or to prevent its loss. Where appropriate, a record should be made of all readings, settings and positions of switches, valves, dials, gauges and indicators, together with photographic evidence and eyewitness reports.

N.B: Consideration should be given to the practicality and implications of quarantining the device; for example if the device is an implantable device all further supplies of the device should be quarantined as a precaution until further advice is sought.

The Investigator and the Sponsor will undertake any requirements outlined in the MHRA investigation and follow-up as instructed.

8 Follow up of Adverse Events by Sponsor
Acknowledgement will be issued to the Investigator from the Sponsor via email within 7 days of receipt of a fully completed form, and this must be filed in the TMF/ISF.

Each SAE/SADE/USADE will be registered on the recognised Sponsor database and reviewed by the Sponsor or their delegate, as per Appendix 6 (Medical Device SAE/SADE review process flowchart). This review may lead to queries being issued by
the Sponsor/delegate to request signed documentation, clarify information or complete event outcome. All queries will be sent via email and must be responded to within the stated timeframe as per the SAE/SADE Template Email (Appendix 7).

All SAE/SADE/USADE reported to the Sponsor will be reviewed at the R&I Management Meeting by the Director of R&I, discussed at the Research Sponsorship Monitoring & Oversight Group (RSMOG), then ratified at the Research Sponsorship Committee (RSC).

9 Documentation

The following documentation must be available in the Trial Master File (TMF)/Investigator Site File (ISF):

- SAE, SADE, USADE reports and follow-up information
- Adverse event/device effect document (Appendix 2)
- Evidence of submission and receipt of SAE/SADEs to the Sponsor and regulatory agencies within the required timeframe
- Evidence of timely notifications to the MHRA and main REC

The investigator must ensure that all SAE/SADE/USADE information is recorded accurately in the medical notes and the study CRF.

10 Non-Compliance

Where evidence of non-compliance is identified the Non-Compliance SOP S-1016 UoL will be followed. Corrective actions will be expected in accordance with MAJOR findings.
### 11 Responsibilities

<table>
<thead>
<tr>
<th>Responsibility</th>
<th>Undertaken by</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CI/PI/Delegated Individual</td>
<td>CI/PI/Delegated Individual</td>
</tr>
<tr>
<td>2</td>
<td>CI/PI/Delegated Individual</td>
<td>CI/PI/Delegated Individual</td>
</tr>
<tr>
<td>3</td>
<td>CI/Delegated Individual</td>
<td>CI/Delegated Individual</td>
</tr>
<tr>
<td>4</td>
<td>Sponsor</td>
<td>Sponsor or designee</td>
</tr>
<tr>
<td>5</td>
<td>CI/PI/Delegated individual</td>
<td>CI/PI/Delegated individual</td>
</tr>
<tr>
<td>6</td>
<td>Sponsor</td>
<td>Sponsor</td>
</tr>
<tr>
<td>7</td>
<td>Sponsor</td>
<td>Research Quality Assurance Officer (RQAO)</td>
</tr>
</tbody>
</table>

This table is used to track the development and approval of the document and any changes made on revised / reviewed versions.

### Development and approval Record for this document

<table>
<thead>
<tr>
<th>Author/Lead Officer:</th>
<th>Cat Taylor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Job Title:</td>
<td>Head of Research Assurance</td>
</tr>
<tr>
<td>Reviewed by:</td>
<td>Research Sponsorship Management and Operations Group</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Professor Nigel Brunskill</td>
</tr>
<tr>
<td>Date Approved:</td>
<td>13/10/2021</td>
</tr>
</tbody>
</table>

### Review Record

<table>
<thead>
<tr>
<th>Date</th>
<th>Issue Number</th>
<th>Reviewed By</th>
<th>Description Of Changes (If Any)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept 2021</td>
<td>1.1</td>
<td>Cat Taylor</td>
<td>Administrative changes.</td>
</tr>
</tbody>
</table>

### Distribution Record

<table>
<thead>
<tr>
<th>Date</th>
<th>Name</th>
<th>Department</th>
<th>Received</th>
</tr>
</thead>
</table>

[Image and text content as provided]